NPI 1912905464: Open Payments
NPI 1912905464. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,275 in 71 payments from 26 companies in 2025. Trend: 2023 $1,225 · 2024 $1,051 · 2025 $1,275
Food & beverage: $1,275
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $182 |
| Abbott Laboratories | 8 | $137 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $91 |
| Lilly USA, LLC | 5 | $87 |
| ABBVIE INC. | 5 | $79 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| PFIZER INC. | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Dexcom, Inc. | 3 | $52 |
| Boston Scientific Corporation | 2 | $48 |
Products named: FREESTYLE LIBRE 3, Ozempic, MOUNJARO, TRELEGY ELLIPTA, Wegovy, JARDIANCE, VOQUEZNA, REXULTI.
